Programme G. T. .2011 .. int/publications/i/item/9789 241564380, : .
Lung Association American .2012 .. Accessed February 9, : .
Tavitian S. M.,Spalek V. H.,Bailey R. P. .2003 .A pharmacist-managed clinic for treatment of latent tuberculosis infection in health care workers. American Journal of Health-system Pharmacy, 60(18) : 1856-1861.
Troy D. B.,Beringer P. .2006 .. Remington: The Science and Practice of Pharmacy. Lippincott Williams & Wilkins., : .
Dye C. .2006 .Global epidemiology of tuberculosis. The Lancet, 367(9514) : 938-940.
Programme G. T. .2011 .. int/publications/i/item/9789 241564380, 1 : .
. .. php?article_id=2 34, : .
Bennett GL,Dolin JE,R JE .2010 .Principles and practice of infectious diseases. , : 3129-3164.
Corbett EL,Marston B,Churchyard CJ .2012 .Risk of transmission www. Accessed March 9, : .
Mazurek G. H.,Jereb J. A.,Vernon A.,Lobue P. A.,Goldberg S.,Castro K. G.,States K. G. .2010 .Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection. nlm.nih.gov/20577159, 59 : 1-25.
Ena J.,Valls V. .2005 .Short-Course Therapy with Rifampin plus Isoniazid, Compared with Standard Therapy with Isoniazid, for Latent Tuberculosis Infection: A Meta-analysis. Clinical Infectious Diseases/Clinical Infectious Diseases (Online, 40(5) : 670-676.
Jereb J. A.,Goldberg S.,Powell K. M.,Villarino M. E.,LoBue P. .2011 .Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. Recommendations for Use of an IsoniazidRifapentine Regimen With Direct Observation to Treat Latent Mycobacterium Tuberculosis Infection. , : .
Horne R.,Barber N.,Weinman J.,Ra E.,Cribb M.,A. M. .2006 .-delivery-andorganisation-rd-programme-concordanceadherence-and-compliance-in-medicinetaking(5ed745f3-a769-47bd-a54b09f1c8768e8a)/export. , : .
Cramer J. A.,Roy A.,Burrell A.,Fairchild C.,Fuldeore M.,Ollendorf D. A.,Wong P. .2007 .Medication Compliance and Persistence: Terminology and Definitions. , 00213(1) : 4733-47.
Cuneo W. D.,Snider D. E. .1989 .Enhancing Patient Compliance with Tuberculosis Therapy. Clinics in Chest Medicine, 5231(21) : 00640-7.
WHO .2002 .An expanded DOTS framework for effective tuberculosis control. nlm.nih.gov/12019913, 6(5) : 378-388.
Last J. M.,Kozakiewicz J. .2009 .Development of a pharmacist-managed latent tuberculosis clinic. American Journal of Health-system Pharmacy, 66(17) : 1522-1523.
Clark P. M.,Karagöz T.,Apikoğlu-Rabuş Ş.,İzzettin F. .2007 .Effect of pharmacist-led patient education on adherence to tuberculosis treatment. American Journal of Health-system Pharmacy, 64(5) : 497-505.
FDC containing Rifampicin 150mg,Isoniazid 75mg,Pyrazinamide 400mg . .. Ethambutol 275mg, : .
. .(RHZE) for 2 months according to body weight bands. , : .
FDC containing Rifampicin 150mg,Isoniazid 75mg . .. , : .
Ethambutol 275mg . .. , : .
. .IInjStreptomycin (500-750 mg) (RRHZES for 2 months. , : .
. .EEthambutol(RRHZE for 1month. , : .
. .. , : .
. .100mg/ml. , : .
. .. , : .
. .. , : .
. .. , : .
. .150mg/ml 4mg. , : .
. .10mg/ml 1g. , : .
. .. , : .
. .2 tbs b. , : .